

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 5, lines 20-31 and replace it with the following paragraph:

According to a second aspect, therefore, the present invention provides an amino acid sequence:

Ser Val Ala Lys Lys His Pro **(SEQ ID NO: 1)**;

an amino acid sequence:

Asp Glu Asp Glu Asn Gln Ser **(SEQ ID NO: 2)**; and

an amino acid sequence:

Asp Gln Arg Gln Gly Ala Glu **(SEQ ID NO: 3)**.

Please delete the paragraph bridging page 6, line 17 to page 7, line 10 and replace it with the following paragraph:

Hence, according to a third aspect, the present invention provides an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor. Advantageously, this inhibitor is characterized in that it comprises a protease inhibitor. Examples of protease inhibitors that can be used as anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitors within the context of the present invention, without being limited thereto, are fluorophosphate-type inhibitors, such as DFP for example, or sulphonyl fluoride-type inhibitors, such as PMSF or AEBSF (4-(2-aminoethyl)benzenesulphonyl fluoride hydrochloride (notably marketed by Roche Diagnostics GmbH, Mannheim, Germany, under the trademark Pefabloc®)), for example. More particularly, this inhibitor is characterized in that said inhibitor inhibits cleavage of the scissile bonds: Arg³⁷²-Ser³⁷³, located between the A1 domains, Tyr¹⁶⁸⁰-Asp¹⁶⁸¹, located on the N-terminus of the A3 domain, and Glu¹⁷⁹⁴-Asp¹⁷⁹⁵ located within the A3 domain of the Factor VIII molecule. More preferably still, this inhibitor is characterized in that it comprises a peptide or non-peptide analogue of the amino acid sequence:

Ser Val Ala Lys Lys His Pro **(SEQ ID NO: 1)**;

a peptide or non-peptide analogue of the amino acid sequence:

Asp Glu Asp Glu Asn Gln Ser **(SEQ ID NO: 2)**; or

a peptide or non-peptide analogue of the amino acid sequence :

Asp Gln Arg Gln Gly Ala Glu **(SEQ ID NO: 3)**.

The Factor VIII degradation inhibitors as defined supra, as well as their addition salts, in particular their pharmaceutically acceptable addition salts, have a very valuable pharmacological profile in that they possess neutralizing activity towards anti-Factor VIII allo-antibodies.

Please delete the table on page 20 and replace it with the following table:

Amino acid sequence	Cleavage site
Ser Val Ala Lys Lys His Pro (SVAKKHP) <u>(SEQ ID NO: 1)</u>	Arg ³⁷² – Ser ³⁷³ (R ³⁷² – S ³⁷³)
Asp Gln Arg Gln Gly Ala Glu (DQRQGAE) <u>(SEQ ID NO: 3)</u>	Glu ¹⁷⁹⁴ – Asp ¹⁷⁹⁵ (E ¹⁷⁹⁴ – D ¹⁷⁹⁵)
Asp Glu Asp Glu Asn Gln Ser (DEDENQS) <u>(SEQ ID NO: 2)</u>	Tyr ¹⁶⁸⁰ – Asp ¹⁶⁸¹ (Y ¹⁶⁸⁰ – D ¹⁶⁸¹)